As investors, we are all looking to get in on the ground floor of a fantastic stock both for returns and maybe, gloating rights to our friends. Some of the best performing stocks are in the healthcare and biotechnology sectors with industry stocks making up 7% of ASX200 companies. With many target diseases and conditions,
Read More
In biotech circles, tackling a rare and difficult disease with few patients does not necessarily equate to targeting an unprofitable one. In the case of fibrotic diseases specialist Pharmaxis (ASX: PXS), its proposed treatment for the rare blood cancer myelofibrosis presents a potential billion dollar-plus market, even though only about 15 in every 1 million
Read More